NCT06879600 High-Flow Nasal Oxygen for Preoxygenation in Emergency Surgery Patients With Full Stomachs
| NCT ID | NCT06879600 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nguyen Dang Thu |
| Condition | High-flow Nasal Cannula |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-07-19 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-07-19 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with full stomachs face a high risk of regurgitation and aspiration under general anesthesia. To minimize the time between the loss of airway protective reflexes and successful tracheal intubation, rapid sequence induction intubation is commonly used. However, these patients are particularly vulnerable to hypoxemia during anesthesia induction, especially in emergency cases. Pre-oxygenation before induction is crucial for ensuring patient safety during apnea. High-flow nasal oxygen (HFNO) therapy, which consists of an air/oxygen blender, an active humidifier, and a single heated circuit, has recently gained widespread use in intensive care units (ICUs) for managing hypoxemic respiratory failure. HFNC can deliver a constant fraction of inspired oxygen (FiO₂) from 0.21 to 1.0 at high flow rates (up to 60 L/min or higher). Its advantages include generating continuous positive airway pressure, reducing anatomical dead space, improving ventilation-perfusion matching, enhancing mucociliary clearance, and decreasing the work of breathing. Given these benefits, HFNO has the potential to improve pre-oxygenation before and during anesthesia induction in emergency surgery patients with full stomachs.
Eligibility Criteria
Inclusion Criteria: * Emergency surgical patients at risk of gastric fullness requiring endotracheal intubation. * Patients aged 18 years or older. * Health status classified as ASA I or II. * Mallampati classification I or II. Exclusion Criteria: * Patients with a predicted difficult airway, facial deformities, or an inability to achieve a proper mask seal. * Patients with respiratory diseases. * Pregnant patients. * Patients allergic to anesthesia or resuscitation drugs. * Patients who do not consent to participate in the study.
Contact & Investigator
Lam Nguyen Duc, Assoc.Prof, PhD, MD
STUDY DIRECTOR
Hanoi Medical University
Frequently Asked Questions
Who can join the NCT06879600 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying High-flow Nasal Cannula. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06879600 currently recruiting?
Yes, NCT06879600 is actively recruiting participants. Contact the research team at Drhong88gmhs@gmail.com for enrollment information.
Where is the NCT06879600 trial being conducted?
This trial is being conducted at Viet Tri, Vietnam.
Who is sponsoring the NCT06879600 clinical trial?
NCT06879600 is sponsored by Nguyen Dang Thu. The principal investigator is Lam Nguyen Duc, Assoc.Prof, PhD, MD at Hanoi Medical University. The trial plans to enroll 200 participants.